Increasing expression of hypoxia-inducible proteins in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence

British Journal of Cancer

Volumn 96, Issue 9, 2007, Pages 1377-1383

  Griffiths, E A ^a,b   Pritchard, S A ^b   McGrath, S M ^b   Valentine, H R ^a   Price, P M ^a   Welch, I M ^b   West, C M L ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Barrett's oesophagus; HIF 1 ; HIF 2 ; Hypoxia; VEGF

Indexed keywords

ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; GLUCOSE TRANSPORTER 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; KI 67 ANTIGEN; PARAFFIN; VASCULOTROPIN;

ARTICLE; BARRETT ESOPHAGUS; CALCULATION; CANCER GROWTH; CARCINOGENESIS; COLUMNAR EPITHELIUM; DISEASE COURSE; DYSPLASIA; ENDOSCOPIC BIOPSY; ESOPHAGEAL ADENOCARCINOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTESTINE METAPLASIA; METAPLASIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS EPITHELIUM;

ADENOCARCINOMA; BARRETT ESOPHAGUS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; BIOPSY; DISEASE PROGRESSION; EPITHELIAL CELLS; ESOPHAGEAL DISEASES; ESOPHAGEAL NEOPLASMS; ESOPHAGUS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; METAPLASIA; RECEPTORS, ERYTHROPOIETIN; REFERENCE VALUES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34247634690     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603744     Document Type: Article

References (47)

1. Acs G, Xu X, Chu C, Acs P, Verma A (2004) Prognostic significance of erythropoietin expression in human endometrial carcinoma. Cancer 100: 2376-2386
2. Acs G, Zhang PJ, McGrath CM, Acs P, McBroom J, Mohyeldin A, Liu S, Lu H, Verma A (2003) Hypoxia-inducible erythropoietin signaling in squamous dysplasia and squamous cell carcinoma of the uterine cervix and its potential role in cervical carcinogenesis and tumor progression. Am J Pathol 162: 1789-1806
3. Acs G, Zhang PJ, Rebbeck TR, Acs P, Verma A (2002) Immunohistochemical expression of erythropoietin and erythropoietin receptor in breast carcinoma. Cancer 95: 969-981
4. Auvinen MI, Sihvo EI, Ruohtula T, Salminen JT, Koivistoinen A, Siivola P, Ronnholm R, Ramo JO, Bergman M, Salo JA (2002) Incipient angiogenesis in Barrett's epithelium and lymphangiogenesis in Barrett's adenocarcinoma. J Clin Oncol 20: 2971-2979
5. Bani-Hani K, Martin IG, Hardie LJ, Mapstone N, Briggs JA, Forman D, Wild CP (2000) Prospective study of cyclin D1 overexpression in Barrett's esophagus: association with increased risk of adenocarcinoma. J Natl Cancer Inst 92: 1316-1321
6. Bani-Hani KE, Bani-Hani BK, Martin IG (2005) Characteristics of patients with columnar-lined Barrett's esophagus and risk factors for progression to esophageal adenocarcinoma. World J Gastroenterol 11: 6807-6814
7. Bergman JJ, Tytgat GN (2005) New developments in the endoscopic surveillance of Barrett's oesophagus. Gut 54(Suppl 1): i38-i42
8. Bertheau P, Cazals-Hatem D, Meignin V, de Roquancourt A, Verola O, Lesourd A, Sene C, Brocheriou C, Janin A (1998) Variability of immunohistochemical reactivity on stored paraffin slides. J Clin Pathol 51: 370-374
9. Bos R, Zhong H, Hanrahan CF, Mommers EC, Semenza GL, Pinedo HM, Abeloff MD, Simons JW, van Diest PJ, van der Wall E (2001) Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis. J Natl Cancer Inst 93: 309-314
10. Corley DA, Levin TR, Habel LA, Weiss NS, Buffler PA (2002) Surveillance and survival in Barrett's adenocarcinomas: a population-based study. Gastroenterology 122: 633-640
11. Costa A, Coradini D, Carrassi A, Erdas R, Sardella A, Daidone MG (2001) Re: Levels of hypoxia-inducible factor-1alpha during breast carcinogenesis. J Natl Cancer Inst 93: 1175-1177
12. Couvelard A, Paraf F, Gratio V, Scoazec JY, Henin D, Degott C, Flejou JF (2000) Angiogenesis in the neoplastic sequence of Barrett's oesophagus. Correlation with VEGF expression. J Pathol 192: 14-18
13. Feith M, Stein HJ, Mueller J, Siewert JR (2004) Malignant degeneration of Barrett's esophagus: the role of the Ki-67 proliferation fraction, expression of E-cadherin and p53. Dis Esophagus 17: 322-327
14. Feldman L, Wang Y, Rhim JS, Bhattacharya N, Loda M, Sytkowski AJ (2006) Erythropoietin stimulates growth and STAT5 phosphorylation in human prostate epithelial and prostate cancer cells. Prostate 66: 135-145
15. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, Semenza GL (1996) Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 16: 4604-4613
16. Grasso G, Sfacteria A, Cerami A, Brines M (2004) Erythropoietin as a tissue-protective cytokine in brain injury: what do we know and where do we go? Neuroscientist 10: 93-98
17. Griffiths EA, Pritchard SA, Valentine HR, Whitchelo N, Bishop PW, Ebert MP, Price PM, Welch IM, West CM (2007) Hypoxia-inducible factor-1alpha expression in the gastric carcinogenesis sequence and its prognostic role in gastric and gastro-oesophageal adenocarcinomas. Br J Cancer 96: 95-103
18. Guindi M, Riddell RH (2003) Histology of Barrett's esophagus and dysplasia. Gastrointest Endosc Clin N Am 13: 349-368, , viii
19. Guzy RD, Hoyos B, Robin E, Chen H, Liu L, Mansfield KD, Simon MC, Hammerling U, Schumacker PT (2005) Mitochondrial complex III is required for hypoxia-induced ROS production and cellular oxygen sensing. Cell Metab 1: 401-408
20. Hardee ME, Arcasoy MO, Blackwell KL, Kirkpatrick JP, Dewhirst MW (2006) Erythropoietin biology in cancer. Clin Cancer Res 12: 332-339
21. Huang SP, Wu MS, Shun CT, Wang HP, Hsieh CY, Kuo ML, Lin JT (2005) Cyclooxygenase-2 increases hypoxia-inducible factor-1 and vascular endothelial growth factor to promote angiogenesis in gastric carcinoma. J Biomed Sci 12: 229-241
22. Ibrahim NB (2000) ACP. Best Practice No 155. Guidelines for handling oesophageal biopsies and resection specimens and their reporting. J Clin Pathol 53: 89-94
23. Iftikhar SY, Steele RJ, Watson S, James PD, Dilks K, Hardcastle JD (1992) Assessment of proliferation of squamous, Barrett's and gastric mucosa in patients with columnar lined Barrett's oesophagus. Gut 33: 733-737
24. Jankowski JA, Wright NA, Meltzer SJ, Triadafilopoulos G, Geboes K, Casson AG, Kerr D, Young LS (1999) Molecular evolution of the metaplasia-dysplasia- adenocarcinoma sequence in the esophagus. Am J Pathol 154: 965-973
25. Jenkins GJ, Doak SH, Parry JM, D'Souza FR, Griffiths AP, Baxter JN (2002) Genetic pathways involved in the progression of Barrett's metaplasia to adenocarcinoma. Br J Surg 89: 824-837
26. Jimenez P, Piazuelo E, Sanchez MT, Ortego J, Soteras F, Lanas A (2005) Free radicals and antioxidant systems in reflux esophagitis and Barrett's esophagus. World J Gastroenterol 11: 2697-2703
27. Keighley MR (2003) Gastrointestinal cancers in Europe. Aliment Pharmacol Ther 18(Suppl 3): 7-30
28. Kim SH, Shin YK, Lee KM, Lee JS, Yun JH, Lee SM (2003) An improved protocol of biotinylated tyramine-based immunohistochemistry minimizing nonspecific background staining. J Histochem Cytochem 51: 129-132
29. Kumar SM, Acs G, Fang D, Herlyn M, Elder DE, Xu X (2005) Functional erythropoietin autocrine loop in melanoma. Am J Pathol 166: 823-830
30. Lord RV, Park JM, Wickramasinghe K, DeMeester SR, Oberg S, Salonga D, Singer J, Peters JH, Danenberg KD, Demeester TR, Danenberg PV (2003) Vascular endothelial growth factor and basic fibroblast growth factor expression in esophageal adenocarcinoma and Barrett esophagus. J Thorac Cardiovasc Surg 125: 246-253
31. McManus DT, Olaru A, Meltzer SJ (2004) Biomarkers of esophageal adenocarcinoma and Barrett's esophagus. Cancer Res 64: 1561-1569
32. Mobius C, Stein HJ, Becker I, Feith M, Theisen J, Gais P, Jutting U, Siewert JR (2003) The 'angiogenic switch' in the progression from Barrett's metaplasia to esophageal adenocarcinoma. Eur J Surg Oncol 29: 890-894
33. Morris CD, Armstrong GR, Bigley G, Green H, Attwood SE (2001) Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence. Am J Gastroenterol 96: 990-996
34. Odze RD (2006) Diagnosis and grading of dysplasia in Barrett's oesophagus. J Clin Pathol 59: 1029-1038
35. Olapade-Olaopa EO, Ogunbiyi JO, MacKay EH, Muronda CA, Alonge TO, Danso AP, Moscatello DK, Sandhu DP, Shittu OB, Terry TR, Wong AJ, Habib FK (2001) Further characterization of storage-related alterations in immunoreactivity of archival tissue sections and its implications for collaborative multicenter immunohistochemical studies. Appl Immunohistochem Mol Morphol 9: 261-266
36. Olyaee M, Sontag S, Salman W, Schnell T, Mobarhan S, Eiznhamer D, Keshavarzian A (1995) Mucosal reactive oxygen species production in oesophagitis and Barrett's oesophagus. Gut 37: 168-173
37. Perneger TV (1998) What's wrong with Bonferroni adjustments. BMJ 316: 1236-1238
38. Polkowski W, van Lanschot JJ, Ten Kate FJ, Baak JP, Tytgat GN, Obertop H, Voorn WJ, Offerhaus GJ (1995) The value of p53 and Ki67 as markers for tumour progression in the Barrett's dysplasia-carcinoma sequence. Surg Oncol 4: 163-171
39. Pouyssegur J, Mechta-Grigoriou F (2006) Redox regulation of the hypoxia-inducible factor. Biol Chem 387: 1337-1346
40. Preston SL, Jankowski JA (2006) Drinking from the fountain of promise: biomarkers in the surveillance of Barrett's oesophagus - the glass is half full!. Gut 55: 1377-1379
41. Reid BJ, Sanchez CA, Blount PL, Levine DS (1993) Barrett's esophagus: cell cycle abnormalities in advancing stages of neoplastic progression. Gastroenterology 105: 119-129
42. Schlemper RJ, Riddell RH, Kato Y, Borchard F, Cooper HS, Dawsey SM, Dixon MF, Fenoglio-Preiser CM, Flejou JF, Geboes K, Hattori T, Hirota T, Itabashi M, Iwafuchi M, Iwashita A, Kim YI, Kirchner T, Klimpfinger M, Koike M, Lauwers GY, Lewin KJ, Oberhuber G, Offner F, Price AB, Rubio CA, Shimizu M, Shimoda T, Sipponen P, Solcia E, Stolte M, Watanabe H, Yamabe H (2000) The Vienna classification of gastrointestinal epithelial neoplasia. Gut 47: 251-255
43. Spechler SJ, Goyal RK (1996) The columnar-lined esophagus, intestinal metaplasia, and Norman Barrett. Gastroenterology 110: 614-621
44. Streitz Jr JM, Andrews Jr CW, Ellis Jr FH (1993) Endoscopic surveillance of Barrett's esophagus. Does it help? J Thorac Cardiovasc Surg 105: 383-387; discussion 387-388
45. Yasuda Y, Fujita Y, Matsuo T, Koinuma S, Hara S, Tazaki A, Onozaki M, Hashimoto M, Musha T, Ogawa K, Fujita H, Nakamura Y, Shiozaki H, Utsumi H (2003) Erythropoietin regulates tumour growth of human malignancies. Carcinogenesis 24: 1021-1029
46. Younes M, Ertan A, Lechago LV, Somoano J, Lechago J (1997) Human erythrocyte glucose transporter (Glut1) is immunohistochemically detected as a late event during malignant progression in Barrett's metaplasia. Cancer Epidemiol Biomarkers Prev 6: 303-305
47. Younes M, Lechago J, Chakraborty S, Ostrowski M, Bridges M, Meriano F, Solcher D, Barroso A, Whitman D, Schwartz J, Johnson C, Schmulen AC, Verm R, Balsaver A, Carlson N, Ertant A (2000) Relationship between dysplasia, p53 protein accumulation, DNA ploidy, and Glut1 overexpression in Barrett metaplasia. Scand J Gastroenterol 35: 131-137